Literature DB >> 22878431

Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid.

F Ginanneschi1, A Mignarri, M Mondelli, G N Gallus, M Del Puppo, S Giorgi, A Federico, A Rossi, M T Dotti.   

Abstract

Polyneuropathy has been reported in cerebrotendinous xanthomatosis (CTX), although its nature and possible association with certain genotypes and phenotypes are unclear. The effect of chronic administration of chenodeoxycholic acid (CDCA) on peripheral nerve conduction parameters is still debated. We report clinical, laboratory, and electrophysiological findings in 35 CTX patients. Twenty-six subjects (74.2 %) showed peripheral nerve abnormalities. Polyneuropathy was predominantly axonal (76.9 % of patients) and generally mild. No correlation was found between its presence and clinical or biochemical data. In polyneuropathic patients, CDCA treatment improved electrophysiological conduction parameters, irrespective of the duration of therapy. Improvement mainly concerned nerve conduction velocities, whereas most nerve amplitudes remained unchanged. This means that CDCA treatment did not influence the number of axons activated by maximum electrical stimulation but increased the conduction of the still-excitable fibers. Our findings may suggest that CDCA treatment promotes myelin synthesis in nerve fibers with residual unaffected axons. The effect of therapy may therefore depend largely on the extent of irreversible structural damage to axons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878431     DOI: 10.1007/s00415-012-6630-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Somatosensory and motor evoked potentials in the assessment of cerebrotendinous xanthomatosis before and after treatment with chenodeoxycholic acid: a preliminary study.

Authors:  D Restuccia; V Di Lazzaro; S Servidei; C Colosimo; P Tonali
Journal:  J Neurol Sci       Date:  1992-10       Impact factor: 3.181

2.  Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis.

Authors:  S Guerrera; M L Stromillo; A Mignarri; M Battaglini; S Marino; C Di Perri; A Federico; M T Dotti; N De Stefano
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-11       Impact factor: 10.154

Review 3.  Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid.

Authors:  M Donaghy; R H King; R O McKeran; M S Schwartz; P K Thomas
Journal:  J Neurol       Date:  1990-06       Impact factor: 4.849

4.  Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy.

Authors:  Mark B Bromberg
Journal:  Muscle Nerve       Date:  2011-06       Impact factor: 3.217

5.  Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis.

Authors:  N De Stefano; M T Dotti; M Mortilla; A Federico
Journal:  Brain       Date:  2001-01       Impact factor: 13.501

6.  Neurophysiological study in cerebrotendinous xanthomatosis.

Authors:  Belen Pilo; Gema de Blas; Maria Jesus Sobrido; Carmen Navarro; Francisco Grandas; Francisco J Barrero; Miguel Angel Moya; Adriano Jimenez-Escrig
Journal:  Muscle Nerve       Date:  2011-04       Impact factor: 3.217

7.  Peripheral neuropathy in cerebrotendinous xanthomatosis.

Authors:  A Kuritzky; V M Berginer; A D Korczyn
Journal:  Neurology       Date:  1979-06       Impact factor: 9.910

8.  Cerebrotendinous xanthomatosis with a compound heterozygote mutation and severe polyneuropathy.

Authors:  Zhaoxia Wang; Yun Yuan; Wei Zhang; Ying Zhang; Liqun Feng
Journal:  Neuropathology       Date:  2007-02       Impact factor: 1.906

9.  De- and remyelination and onion bulb in cerebrotendinous xanthomatosis.

Authors:  A Ohnishi; Y Yamashita; I Goto; Y Kuroiwa; S Murakami; M Ikeda
Journal:  Acta Neuropathol       Date:  1979-01-12       Impact factor: 17.088

10.  Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX).

Authors:  P H Pop; E Joosten; A van Spreeken; A Gabreëls-Festen; H Jaspar; H ter Laak; A Vos
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

View more
  14 in total

Review 1.  Inherited neuropathies: an update.

Authors:  Anna Sagnelli; Giuseppe Piscosquito; Davide Pareyson
Journal:  J Neurol       Date:  2013-09-24       Impact factor: 4.849

2.  Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Alessandro Magni; Marina Del Puppo; Gian Nicola Gallus; Ingemar Björkhem; Antonio Federico; Maria Teresa Dotti
Journal:  J Inherit Metab Dis       Date:  2015-07-08       Impact factor: 4.982

3.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Gian Nicola Gallus; Maria Teresa Dotti; Antonio Federico
Journal:  J Inherit Metab Dis       Date:  2014-01-18       Impact factor: 4.982

4.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

Review 5.  Effects of bile acids on neurological function and disease.

Authors:  Matthew McMillin; Sharon DeMorrow
Journal:  FASEB J       Date:  2016-07-28       Impact factor: 5.191

Review 6.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

7.  Patients with cerebrotendinous xanthomatosis diagnosed with diverse multisystem involvement.

Authors:  Pelin Teke Kısa; Gonca Kilic Yildirim; Burcu Ozturk Hismi; Sevil Dorum; Ozge Yilmaz Kusbeci; Ali Topak; Figen Baydan; Fatma Nazlı Durmaz Celik; Orhan Gorukmez; Zumrut Arslan Gulten; Arzu Ekici; Serhat Ozkan; Aylin Yaman; Nur Arslan
Journal:  Metab Brain Dis       Date:  2021-03-11       Impact factor: 3.584

Review 8.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

9.  Sonographic Findings of Polyneuropathy Associated With Cerebrotendinous Xanthomatosis: A Case Report.

Authors:  Jung Yoon Yoon; Min-Wook Kim; Hyun Jung Do; Dae-Hyun Jang; Hee Won Lee
Journal:  Ann Rehabil Med       Date:  2017-04-27

Review 10.  The Intersection Between Cerebellar Ataxia and Neuropathy: a Proposed Classification and a Diagnostic Approach.

Authors:  Cristina Saade Jaques; Marcio Luiz Escorcio-Bezerra; José Luiz Pedroso; Orlando Graziani Povoas Barsottini
Journal:  Cerebellum       Date:  2021-08-09       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.